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Abstract
Aims/hypothesis The PPARGC1A gene coactivates multiple
nuclear transcription factors involved in cellular energy
metabolism and vascular stasis. In the present study, we
genotyped 35 tagging polymorphisms to capture all
common PPARGC1A nucleotide sequence variations and
tested for association with metabolic and cardiovascular
traits in 2,101 Danish and Estonian boys and girls from the
European Youth Heart Study, a multicentre school-based
cross-sectional cohort study.
Methods Fasting plasma glucose concentrations, anthropo-
metric variables and blood pressure were measured.
Habitual physical activity and aerobic fitness were objec-
tively assessed using uniaxial accelerometry and a maximal
aerobic exercise stress test on a bicycle ergometer,
respectively.
Results In adjusted models, nominally significant asso-
ciations were observed for BMI (rs10018239, p=0.039),
waist circumference (rs7656250, p=0.012; rs8192678
[Gly482Ser], p=0.015; rs3755863, p=0.02; rs10018239,
beta=−0.01 cm per minor allele copy, p=0.043), systolic
blood pressure (rs2970869, p=0.018) and fasting glucose
concentrations (rs11724368, p=0.045). Stronger associa-
tions were observed for aerobic fitness (rs7656250, p=
0.005; rs13117172, p=0.008) and fasting glucose concen-
trations (rs7657071, p=0.002). None remained significant
after correcting for the number of statistical comparisons.
We proceeded by testing for gene × physical activity
interactions for the polymorphisms that showed nominal
evidence of association in the main effect models. None of
these tests was statistically significant.
Conclusions/interpretation Variants at PPARGC1A may
influence several metabolic traits in this European paediat-
ric cohort. However, variation at PPARGC1A is unlikely to
have a major impact on cardiovascular or metabolic health
in these children.
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Introduction
The protein encoded by the PPARGC1A gene coactivates
multiple transcription factors involved in the regulation of
oxidative stress, mitochondrial biogenesis, and lipid and
glucose oxidation. Exposure to cold, exercise and fasting
have all been shown to influence PPARGC1A transcription
rates [1], raising the possibility that the gene interacts with
energy balance behaviours to influence cardiovascular and
metabolic health.
The most frequently studied PPARGC1A polymorphism
is the Gly482Ser (rs8192678) non-synonymous coding
variant. Associations between Gly482Ser and type 2
diabetes [2, 3], hypertension [4], obesity [5], dyslipidaemia
[6–8], aerobic fitness [9] and insulin resistance [10] have
been widely reported. However, a thorough exploration of
common PPARGC1A variants and their associations with
metabolic or cardiovascular disease traits is yet to be
reported in adults or children.
The purpose of the present study was to comprehensive-
ly assess associations between common PPARGC1A
sequence variants and both cardiovascular and metabolic
disease traits in Danish and Estonian children from the
European Youth Heart Study (EYHS).
Methods
Participants and clinical measures The EYHS is a multi-
centre school-based cross-sectional cohort study of Euro-
pean children and adolescents. The methods for the
non-genetic aspects of the study have been reported in
detail previously [11]. This study comprises 1,255 children
(age range boys [8.4–11.2 years] and girls [8.4–11.3 years])
and 846 adolescents (age range: boys [14.1–17.8 years] and
girls [14.1–17.0 years]) from Denmark and Estonia
(Table 1). Written informed consent was obtained from a
parent or guardian and all children gave verbal assent.
Local research ethics committees of the respective centres
approved the study protocol.
Weight, height and waist circumference were measured
using standard anthropometric techniques. BMI was calcu-
lated as weight (kg) divided by height (m2) and was
standardised to age and sex using the methods described by
Cole et al. [12]. Sexual maturity was assessed with the five-
stage Tanner scale for breast development in girls and pubic
hair in boys [13]. Blood pressure was measured with a
paediatric/adult and neonatal vital signs monitor (Dinamap
model XL; Critikron, Tampa, FL, USA). Plasma glucose
was analysed using the hexokinase method, measured with
Table 1 Participant characteristics by age group and sex in the EYHS
Variable Children (n=1,255) Adolescents (n=846)
Boys (n=599) Girls (n=656) Boys (n=376) Girls (n=470)
Age (years) 9.7 (0.4) 9.6 (0.4) 15.5 (0.5) 15.5 (0.5)
Height (cm) 138.9 (6.6) 138.7 (6.7) 174.2 (7.5) 165.3 (5.9)
Weight (kg) 33.2 (6.1) 33.1 (6.8) 62.5 (10.1) 56.2 (8.2)
BMI (kg/m2) 17.1 (2.2) 17.1 (2.6) 20.5 (2.5) 20.6 (2.7)
Overweight (n)a 91 87 37 40
Obese (n) a 38 41 8 6
Waist circumference (cm) 59.4 (5.5) 58.3 (6.6) 71.3 (5.9) 66.8 (5.8)
Diastolic BP (mmHg) 60.2 (7) 60.1 (6.3) 63.1 (6.8) 64.1 (6.3)
Systolic BP (mmHg) 102.7 (8.9) 101 (8.5) 116.3 (11.4) 108.1 (9.1)
Aerobic fitness (W/kg) 3.2 (0.5) 2.8 (0.5) 3.7 (0.6) 2.8 (0.5)
Plasmsa glucose (mmol/l) 5.1 (0.36) 4.97 (0.37) 5.24 (0.45) 5.05 (0.42)
Plasma insulin (pmol/l) 40.2 (22.06) 47.92 (30.66) 72.08 (40.35) 79.37 (36.33)
Total cholesterol (mmol/l) 4.44 (0.73) 4.52 (0.77) 3.97 (0.67) 4.36 (0.77)
Triacylgylcerol (mmol/l) 0.72 (0.33) 0.81 (0.33) 0.81 (0.38) 0.94 (0.4)
HOMA-Bb 129.44 (85.65) 143.12 (90.92) 118.39 (45.41) 137.93 (50.16)
HOMA-Sb 100.23 (62.51) 94.05 (59.63) 78.87 (39.26) 68.32 (31.54)
HDL-cholesterol (mmol/l) 1.57 (0.36) 1.47 (0.29) 1.32 (0.26) 1.42 (0.3)
LDL-cholesterol (mmol/l) 2.54 (0.61) 2.68 (0.66) 2.28 (0.57) 2.5 (0.66)
Physical activity (counts/min) 742.3 (234.7) 613.4 (188.1) 550.1 (237) 451.1 (164.6)
Data are means (±SD)
a The number of individuals with BMI between the 85th and 95th (overweight), and ≥95th (obese) percentiles, respectively
b Using the calculator available at www.dtu.ox.ac.uk/index.php?maindoc=/homa/index.php, accessed 1 March 2008
HOMA-B, homeostasis model of beta cell function; HOMA-S, homeostasis model of insulin sensitivity
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an autoanalyser (AU600; Olympus Diagnostica, Olympus
America, Center Valley, PA, USA). Habitual physical
activity was assessed using uniaxial accelerometry (MTI
Actigraph, WAM 7164; MTI, Fort Walton Beach, FL,
USA) during two weekdays and two weekend days of free-
living. The outcome variable in this report is expressed as
total counts per unit time (counts/min), which is an indicator
of the total volume of activity (i.e. average intensity of activ-
ity). Aerobic fitness was assessed during an incremental-load
exercise stress test to exhaustion on an electronically braked
bicycle ergometer (Monark 839; Ergomedic, Varberg,
Sweden). Aerobic fitness is expressed as maximally attained
mechanical power relative to body weight (W/kg).
Genetic analyses To capture all common PPARGC1A se-
quence variation (±10 kb) we undertook pair-wise tagging
(r2>0.8 and minor allele frequency >0.05) using the Tagger
software in Haploview (www.broad.mit.edu/mpg/haploview,
accessed 1 May 2008) to select 35 tagging polymorphisms
from the CEU (Centre d'Etude du Polymorphisme Humain
trios originating from northern and western Europe living in
Utah, USA) phase 2 HAPMAP (release 19, NCBI build 34)
database (for overview of HAPMAP coverage, see Elec-
tronic supplementary material [ESM] Table 1). Almost all
PPARGC1A genotyping was performed using the Illumina
Beadstation custom-array (Illumina, San Diego, CA, USA).
The exception was for Gly482Ser (rs8192678), which was
genotyped at the MRC Epidemiology Unit genotyping
facility using TaqMan (Applied Biosystems, Foster City,
CA, USA). A total of 62 DNA samples were of inadequate
quality and failed for all assays. Therefore, these were
excluded from the dataset. The phenotypic characteristics of
these samples did not differ from the remainder of the co-
hort. The genotyping success rate for all SNPs on the
Illumina platform exceeded 98%. The success rate of the
TaqMan genotyped Gly482Ser (rs8192678) variant was
96.4%. All polymorphisms were in Hardy–Weinberg
equilibrium (p>0.05), which was assessed using a likeli-
hood ratio test (ESM Table 2). The minor allele frequencies
of the polymorphisms ranged from 0.05 to 0.47 (ESM
Table 2). Pair-wise correlations between variants ranged
from r2=0.01 to r2=0.90.
Statistical power Calculations were performed using plau-
sible effect sizes (i.e. a beta equivalent to 0.005, 0.01 and
0.015% phenotypic difference per copy of the effective
allele) and for a range of minor allele frequencies (0.05–
0.45) using QUANTO (V1.2.3) [14] (ESM Fig. 1a–f).
Statistical analysis Statistical analyses were conducted
using SAS software (version 9.1; SAS Institute, Cary, NC,
USA). Waist circumference and glucose were logarithmi-
cally transformed to normalise their distribution. General-
ised linear models were used to test associations between
each polymorphism and each outcome trait assuming an
additive genetic model. All models were adjusted for
country, age, age group, sex and sexual maturity. Adjusting
for study centre instead of country did not materially affect
the results. Where BP was the dependent variable, adjust-
ments were also made for height and weight. To assess the
putative effect modifying roles of age, country or physical
activity, interaction terms were fitted to the linear models.
Adjustments for multiple statistical comparisons were made
using the Holm procedure [15]. Using this approach, the p
values for the hypothesis tests are ranked, with the least
significant appearing at the top of the list. The denominator
for each correction is defined by the number of tests within
that rank-ordered list with higher p values. Thus, the least
significant hypothesis test is divisible by 1, the second least
significant hypothesis test by 2 and so on until all p values
are corrected. This correction method was applied to each
phenotype separately.
Results
Table 1 shows characteristics of the 1,255 children and
846 adolescents who participated in this study. Signifi-
cant differences by age group and sex were observed in
the proportion of obese individuals within these groups
and the levels of metabolic and cardiovascular traits
(p<0.001).
After adjustment, several nominally significant associ-
ations were observed for BMI (rs10018239 beta=
−0.06 kg/m2 per minor allele copy, p=0.039), waist
circumference (rs10018239 beta=−0.01 cm per minor allele
copy, p=0.043; rs7656250 beta=0.01 cm per minor allele
copy, p=0.012; rs8192678 [Gly482Ser] beta=0.01 cm per
minor allele copy, p=0.015; rs3755863 beta=−0.01 cm per
minor allele copy, p=0.02), SBP (rs2970869 beta=
0.77 mmHg per minor allele copy, p=0.018) and fasting
glucose concentrations (rs11724368 beta=−0.01 mmol/l per
minor allele copy, p=0.045). Stronger associations were
observed for aerobic fitness (rs7656250 beta=−0.06 W/kg
per minor allele copy, p=0.005; rs13117172 beta=0.06 W/kg
per minor allele copy, p=0.008) and fasting glucose
concentrations (rs7657071 beta=−0.01 mmol/l per minor
allele copy, p=0.002). After correcting for multiple compar-
isons (each phenotype separately), the statistical significance
of all models was abolished; the strongest corrected p value
was for fasting glucose (rs7657071, pcorrected=0.07) (see
ESM Tables 3 and 4 for summary of nominal tests).
Table 2 shows associations between the Gly482Ser
polymorphism and a range of previously studied cardio-
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vascular and metabolic traits. In these models, as reported
above, waist circumference was the only nominally
associated trait (p=0.02).
We proceeded by testing interaction terms (gene ×
physical activity, age or country) for each of the poly-
morphisms that showed nominal evidence of association in
the main effect models. None of these interaction tests
approached statistical significance.
Discussion
This is, to our knowledge, the first study to comprehen-
sively examine the role of common PPARGC1A sequence
variation in relation to complex disease traits. We observed
limited evidence supporting the possibility that variants at
PPARGC1A influence metabolic or cardiovascular risk factor
levels in this cohort of European children. The strongest
associations were for the rs7656250 and rs13117172 variants
(with aerobic fitness) and the rs7657071 variant (with fasting
glucose concentrations), which in this cohort are in very low
linkage disequilibrium (LD) (r2=0.13) (see ESM Fig. 1 for
LD plot comparing all SNPs).
PPARGC1A is a strong biological candidate for cardio-
vascular and metabolic disease. Its well established role as a
master regulator of energy metabolism, vascular homeosta-
sis, oxidative stress and adipogenesis has prompted many
papers reporting on associations between PPARGC1A
variants and a range of seemingly plausibly disease traits.
The most widely studied PPARGC1A variant is the
Gly482Ser non-synonymous polymorphism. Since the
initial report of association between this variant and type
2 diabetes [2], many others have reported statistical
associations with diabetes-related traits [3, 5, 7, 9, 10].
Here we observed a nominal statistical association between
Gly482Ser and waist circumference, but no associations
were observed for other traits. There are several possible
explanations for the apparent inconsistency between our
findings and those previously reported. For example, most
existing studies were conducted in adults of advanced age,
from a variety of ethnic backgrounds. By contrast, the
cohort studied here was of relatively healthy children of
northern European ancestry. Most previous studies report
nominally statistically significant findings that are rarely
adjusted for multiple statistical comparisons, predisposing
some to type 2 error. It is also possible that a degree of
publication bias exists, where association studies with
statistically significant findings are disproportionally repre-
sented in the literature. For example, in a recent meta-
analysis of published studies, a statistical association
between the Gly482Ser polymorphism and type 2 diabetes
was reported [3]. However, this finding was not supported
by a meta-analysis of type 2 diabetes genetics conducted in
a somewhat larger total sample [16]. Similarly, in a recent
meta-analysis of Gly482Ser and BP, statistical associations
were evident when including only previously published
data, but these effects were abolished when unpublished
data were also included [4].
PPARGC1A is a relatively large gene, comprised of
eight exons. In European whites, approximately 35 tagging
variants are required to capture all common variation across
the gene. Thus, a caveat to undertaking a comprehensive
study of PPARGC1A is that it involves testing multiple
hypotheses. To diminish the possibility of false discovery,
we present corrected and uncorrected p values for each
nominally significant test. However, it may be that
corrections such as these are overly conservative. This,
combined with the fact that our study was underpowered
for some of the association tests performed (ESM Fig. 2a–f),
should be born in mind when considering the relevance of
some of the negative findings reported herein.
In summary, we have undertaken the first comprehensive
study of PPARGC1A sequence variation. Our findings
suggest that PPARGC1A variation may play a relatively
modest role in regulating some of the cardiovascular and
metabolic traits studied here, with the rs7657071 and
Table 2 Summary of association analyses for the PPARGC1A Gly482Ser polymorphism
Phenotypes
Gly/Gly Gly/Ser Ser/Ser p value
BMI (z score) 0.08 (0.03) 0.12 (0.03) 0.20 (0.07) 0.13
Waist circumference (cm) 62.03 (0.18) 62.27 (0.19) 63.3 (0.43) 0.02
Diastolic BP (mmHg) 61.72 (0.22) 61.46 (0.23) 60.92 (0.5) 0.14
Systolic BP (mmHg) 105.81 (0.29) 105.51 (0.31) 104.92 (0.68) 0.22
Aerobic fitness (W/kg) 3.07 (0.02) 3.06 (0.02) 3.06 (0.04) 0.58
Glucose (mmol/l) 5.05 (0.01) 5.05 (0.01) 5.1 (0.03) 0.27
Data are means (±SD)
All results were adjusted for country, sex, age group, age and maturity. Diastolic BP and systolic BP were also adjusted for height and weight,
glucose was additionally adjusted for analysis centre
BMI was standardised using Cole's LMS method [12]
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rs7656250 variants being the most promising candidates for
future exploration.
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